Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23727471 | 0.90 | MEN1 (0.53) | MEN1MAPTKMT2ACYP2C9CYP2C19 | |
| SCHEMBL29966288 | 0.90 | MEN1 (0.53) | MEN1MAPTKMT2ACYP2C9CYP2C19 | |
| SCHEMBL23727467 | 0.90 | MEN1 (0.53) | MEN1MAPTKMT2ACYP2C9CYP2C19 | |
| SCHEMBL13238745 | 0.87 | MEN1 (0.50) | MEN1MAPTKMT2ACYP2C9CYP2C19 | |
| SCHEMBL13238704 | 0.87 | KMT2A (0.53) | MEN1MAPTKMT2ACYP2C9CYP2C19 | |
| SCHEMBL2955049 | 0.86 | MEN1 (0.49) | MEN1MAPTKMT2ACYP2C9CYP2C19 | |
| SCHEMBL30381603 | 0.84 | MEN1 (0.50) | MEN1MAPTKMT2ACYP2C9CYP2C19 | |
| SCHEMBL8285700 | 0.84 | MEN1 (0.53) | MEN1MAPTKMT2ACYP2C9CYP2C19 | |
| SCHEMBL2923818 | 0.82 | MAPT (0.51) | MEN1MAPTKMT2ACYP2C9CYP2C19 | |
| SCHEMBL28990175 | 0.82 | MEN1 (0.51) | MEN1MAPTKMT2ACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759361-B2 | treating a cancer, autoimmune diseases and cardiovscular disorders comprising administering drugs such as Isobutyric acid 2-isobutyryloxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-ylmethyl ester; antiproliferative agents | APREA AB (SE) | 2010-07-20 | — | — | US | disclosed |
| US-7759361-B2 | treating a cancer, autoimmune diseases and cardiovscular disorders comprising administering drugs such as Isobutyric acid 2-isobutyryloxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-ylmethyl ester; antiproliferative agents | APREA AB (SE) | 2010-07-20 | — | — | US | disclosed |
| US-7759361-B2 | treating a cancer, autoimmune diseases and cardiovscular disorders comprising administering drugs such as Isobutyric acid 2-isobutyryloxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-ylmethyl ester; antiproliferative agents | APREA AB (SE) | 2010-07-20 | — | — | US | disclosed |
| US-20070142370-A1 | Azabicyclooctan-3-one derivatives and use thereof | APREA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142370-A1 | Azabicyclooctan-3-one derivatives and use thereof | APREA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142370-A1 | Azabicyclooctan-3-one derivatives and use thereof | APREA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| EP-1727817-A1 | AZABICYCLOOCTAN-3-ONE DERIVATIVES AND USE THEREOF | APREA AB (SE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005090341-A1 | AZABICYCLOOCTAN-3-ONE DERIVATIVES AND USE THEREOF | APREA AB (SE) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090341-A1 | AZABICYCLOOCTAN-3-ONE DERIVATIVES AND USE THEREOF | APREA AB (SE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142370-A1 | Azabicyclooctan-3-one derivatives and use thereof | CCNA1, CCNY, MALT1 | MEN1 246/4885MAPT 4765/4885KMT2A 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.